Reduce anxiety and improve functioning

Trial ID
NCT07310147
Official Title
Empower Your Mind to Embrace Your Life: Development and Efficacy Study of a Videoconference-delivered Group Intervention Based on Acceptance and Commitment Therapy for People With Young-onset Parkinson's Disease
Goal
Reduce anxiety and improve functioning
Phase
NA
Status
RECRUITING
Sponsor
University of Coimbra
Study Type
INTERVENTIONAL
Enrollment
20 participants
Conditions
Parkinson's Disease (PD)
Interventions
Empower your mind to embrace your life

Plain-Language Summary

Aiming to help people with young-onset Parkinson's manage distress, anxiety, and loss of everyday functioning by increasing psychological flexibility and overall quality of life. It offers a group Acceptance and Commitment Therapy program delivered by videoconference, teaching acceptance of difficult thoughts and sensations, mindfulness, and committed, values-driven action; as a talk-based therapy it complements usual Parkinson's medications like levodopa and does not change how those drugs work. Looking for Portuguese-speaking adults 21 to 65 years old with neurologist-confirmed young-onset PD in Hoehn and Yahr stages 1 to 2.5, and excludes those currently in psychological treatment, pregnant people, anyone with current suicidal ideation, severe psychiatric illness, or cognitive impairment.

Locations

  • CINEICC, Coimbra, Portugal

Frequently Asked Questions

What is this trial testing?
This trial is studying Empower your mind to embrace your life. Aiming to help people with young-onset Parkinson's manage distress, anxiety, and loss of everyday functioning by increasing psychological flexibility and overall quality of life. It offers a group Acceptance and Commitment Therapy program delivered by videoconference, teaching acceptance of difficult thoughts and sensations, mindfulness, and committed, values-driven action; as a talk-based therapy it complements usual Parkinson's medications like levodopa and does not change how those drugs work. Looking for Portuguese-speaking adults 21 to 65 years old with neurologist-confirmed young-onset PD in Hoehn and Yahr stages 1 to 2.5, and excludes those currently in psychological treatment, pregnant people, anyone with current suicidal ideation, severe psychiatric illness, or cognitive impairment.
Who can participate?
Participants must be between 21 Years and 65 Years.
Where is this trial located?
This trial is recruiting at 1 location.
Does it cost anything to join?
No. There is no cost to participate. Study-related care and treatment are provided at no charge.
How long does the trial last?
This trial is estimated to last approximately 1 year and 3 months.

View on ClinicalTrials.gov